With concerns that the disease might have an impact on economic growth, Indonesia plans to conduct clinical trials of a number of vaccines to combat the rising cases of tuberculosis ( TB ) this year, ministers announced on Monday ( Jun 10 ).
The Southeast Asian nation has seen a rise in TB cases over the past few years, with the health department estimating there will be more than 1 million circumstances by 2023, compared to 820, 000 in 2020.
In 2022, incidents from TB in Indonesia reached around 134, 000, the next highest in the world after India.
At a government conference with provincial leaders, people development minister Muhadjir Effendy said that three-quarters of the patients were in the effective age group and that 47 % of the people did not work, raising questions about the impact of the disease’s spread. The minister did not give an estimation of how much the change would affect progress.
Indonesia plans to execute a TB vaccination trial led by international pharmaceutical firm GlaxoSmithKline in July, according to health secretary Budi Gunadi Sadikin. The Bill and Melinda Gates Foundation provides funding for the development of vaccines.
This year, according to Budi, a clinical test for a vaccine produced by China’s CanSino Biologics is likewise planned.
” We hope to be one of the first locations to complete disease vaccination”, Budi told the same conference.
We’re also in the process of conducting a clinical test for an mRNA vaccine that BioNTech is developing, which founded COVID vaccination for Pfizer, according to Budi.
Home Affairs Minister Tito Karnavian also mandated that provincial leaders establish task forces to look into TB diseases at the same time.
By 2030, Indonesia wants to reduce its mortality rate from TB by 80 % to just six deaths per 100 000 life, according to Budi.